No Data
Zejing Pharmaceutical: Zejing Pharmaceutical 2024 Annual Performance Report Announcement
Zejing Pharmaceutical 2024 Annual Results Report Announcement
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) CEO Zelin Sheng Is the Most Upbeat Insider, and Their Holdings Increased by 9.5% Last Week
Suzhou Zelgen BiopharmaceuticalsLtd's (SHSE:688266) Investors Will Be Pleased With Their Favorable 53% Return Over the Last Year
Zejing Pharmaceutical 2024 annual results forecast
Zhejiang Jingxin Pharmaceutical (688266.SH): Expected net loss in 2024 is between 0.11 billion yuan and -0.16 billion yuan.
On January 17, Gelonghui reported that Zhejing Pharmaceutical (688266.SH) announced that (1) after preliminary calculations by the financial department, it is expected to achieve revenue of 517.93 million yuan to 549.88 million yuan for the fiscal year 2024, representing an increase of 34.03% to 42.30% compared to the same period last year. (2) The company expects to achieve a Net income attributable to owners of the parent company ranging from -163.9 million yuan to -109.83 million yuan for fiscal year 2024, a decrease in the loss compared to the same period last year by 114.6827 million yuan to 168.7527 million yuan. (3) The company expects...
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
